A big Cochrane review found that medicines trying to clear amyloid beta in the brain do not help people with Alzheimer’s in a useful way. These drugs may also raise the chance of swelling or bleeding inside the brain.
What Is Amyloid Beta?
Amyloid beta is a tiny protein that builds up in the brains of people who will later develop Alzheimer’s. Scientists thought that removing this protein could slow or stop the disease, so they created several drugs to do just that.
Big Review of Alzheimer’s Drug Trials
The new analysis looked at 17 clinical trials that together involved 20,342 participants. All the studies focused on people who had mild memory problems or early‑stage Alzheimer’s. Researchers hoped that treating the disease early might work best.
Results Were Smaller Than Expected
The review showed that the drugs had almost no effect on memory loss or on how severe the dementia became. Any improvement was far below what doctors consider a meaningful change for patients.
Higher Chance of Brain Swelling and Bleeding
Besides the lack of benefit, the drugs were linked to a greater risk of the brain swelling or bleeding. Often these changes were only seen on scans and did not cause clear symptoms, but we still do not know the long‑term effects.
What This Means for Future Treatments
Because the medicines do not turn into better outcomes, scientists say that focusing on clearing amyloid beta is unlikely to help patients much. Even though the drugs lower amyloid levels, this does not lead to better health.